Gregory S. Cameron

5.2k citations

40 papers · 4.1k indexed · 3 hit papers · h-index 25

Impact in

Dermatology top 0.1%
- Dermatology and Skin Diseases
Immunology top 0.5%
- Psoriasis: Treatment and Pathogenesis

Papers in

Dermatology 17
- Dermatology and Skin Diseases 9
- Skin Protection and Aging 3
Immunology 14
- Psoriasis: Treatment and Pathogenesis 12

Co-authors: Craig L. Leonardi Subhashis Banerjee Daniel Braun Emily Edson‐Heredia Claus Zachariae J. Erickson Linda Li Robert Matheson
Journals: Journal of the American Academy of Dermatology (6 papers)Journal of Investigative Dermatology (3 papers)New England Journal of Medicine (3 papers)The Journal of Dermatology (2 papers)British Journal of Dermatology (2 papers)
Partner nations: United States Japan United Kingdom

In The Last Decade

Gregory S. Cameron

40 papers receiving 4.0k citations

Hit Papers

align trajectories log scale

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis 2016 · 650 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 New England Journal of Medicine
2015 The Lancet
2012 New England Journal of Medicine

Peers

Countries citing papers authored by Gregory S. Cameron

Since Specialization

Citations

This map shows the geographic impact of Gregory S. Cameron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory S. Cameron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory S. Cameron more than expected).

Fields of papers citing papers by Gregory S. Cameron

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory S. Cameron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory S. Cameron. The network helps show where Gregory S. Cameron may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Gregory S. Cameron, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gregory S. Cameron Line = papers co-authored together Gregory S. Cameron links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis Journal of the American Academy of Dermatology ·Claus Zachariae, Kenneth B. Gordon, Alexa B. Kimball, Mark Lebwohl, Andrew Blauvelt, Craig L. Leonardi, Daniel Braun, 文子賀美, Russel Burge, Gregory S. Cameron	2018	25
2	Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3) British Journal of Dermatology ·Kim Papp, C. Leonardi, Andrew Blauvelt, Kristian Reich, A. M. N. Batista, Mamitaro Ohtsuki, C. Paul, Susan Ball, Gregory S. Cameron, J. Erickson, Hans Henrik Fafner, Lotus Mallbris, C.E.M. Griffiths	2017	77
3	Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (UNCOVER‐J) The Journal of Dermatology ·Hidehisa Saeki, Hidemi Nakagawa, Ko Nakajo, Taeko Ishii, Yoji Morisaki, Unegbu Valentine N, Gregory S. Cameron, Olawale Osuntokun, (unknown)	2016	156
4	Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis New England Journal of Medicine ·Kenneth B. Gordon, Andrew Blauvelt, Kim Papp, Richard G. Langley, Thomas A. Luger, Mamitaro Ohtsuki, Kristian Reich, David A. Amato, Susan Ball, Daniel Braun, Gregory S. Cameron, J. Erickson, Robert J. Konrad, Talia M. Muram, Brian J. Nickoloff, Olawale Osuntokun, Roberta J. Secrest, Fangyi Zhao, Lotus Mallbris, Craig L. Leonardi Hit paper breakdown →	2016	650
5	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials The Lancet ·C.E.M. Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, C. Paul, Alan Menter, Gregory S. Cameron, J. Erickson, Lu Zhang, Roberta J. Secrest, Susan Ball, Daniel Braun, Olawale Osuntokun, Michael Heffernan, Brian J. Nickoloff, Kim Papp Hit paper breakdown →	2015	658
6	A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis Journal of the American Academy of Dermatology ·Kenneth B. Gordon, Craig L. Leonardi, Mark Lebwohl, Andrew Blauvelt, Gregory S. Cameron, Daniel Braun, J. Erickson, Michael Heffernan	2014	87
7	A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti–Interleukin‐17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors Arthritis & Rheumatology ·Mark C. Genovese, Maria Greenwald, Chul‐Soo Cho, Alberto Berman, Ling Jin, Gregory S. Cameron, Olivier Bénichou, Li Xie, Daniel Braun, Pierre‐Yves Berclaz, Subhashis Banerjee	2014	174
8	IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis Journal of Allergy and Clinical Immunology ·James G. Krueger, Scott Fretzin, Mayte Suárez‐Fariñas, Patrick Haslett, Krista M Phipps, Gregory S. Cameron, Juliet McColm, Andrada-Oana Spanci, Inna Cueto, Dettori Alessia, Subhashis Banerjee, Robert W. Hoffman	2012	300
9	Modulation of Blood Pressure by Central Melanocortinergic Pathways New England Journal of Medicine ·Jerry R. Greenfield, Jeffrey W. Miller, Julia M. Keogh, Elana Henning, Julie Satterwhite, Gregory S. Cameron, B Astruc, John P. Mayer, Søren Brage, Teik Choon See, David J. Lomas, Stephen O’Rahilly, I. Sadaf Farooqi	2008	360
10	Oxidized Low-Density Lipoprotein and Autoimmune Antibodies in Patients With Antiphospholipid Syndrome With a History of Thrombosis American Journal of Clinical Pathology ·Dandan Zhao, Mohammad Ahmadi Ganjei, Xiang Wang, Gregory S. Cameron, J. Rod eacute s, Jeffrey S. Dlott, Douglas A. Triplett	2001	10
11	Antioxidant Nutrients Protect Against UVB-Induced Oxidative Damage to DNA of Mouse Keratinocytes in Culture Journal of Investigative Dermatology ·and Harry R. Wright, Gregory S. Cameron, Barbara C. Pence	1996	116
12	The effects of chronic sunscreen use on the histologic changes of dermatoheliosis Journal of the American Academy of Dermatology ·Alan S. Boyd, Mark F. Naylor, Gregory S. Cameron, A.D. Pearse, S. Gaskell, Kenneth H. Neldner	1995	70
13	Evaluation of Antigenic Determinant in Chlorocresol and Chloroxylenol Contact Dermatitis by Patch Testing With Chemically Related Substances Dermatitis ·Alexander Zemtsov, Hongfang Liu, Gregory S. Cameron, Candi Citadini de Oliveira	1994	2
14	Human in vivo phosphorus 31 magnetic resonance spectroscopy of psoriasis Journal of the American Academy of Dermatology ·Alexander Zemtsov, Lisa R. Dixon, Gregory S. Cameron	1994	14
15	Evaluation of Antigenic Determinant in Chlorocresol and Chloroxylenol Contact Dermatitis by Patch Testing With Chemically Related Substances American Journal of Contact Dermatitis ·Alexander Zemtsov, Hongfang Liu, Gregory S. Cameron, Candi Citadini de Oliveira	1994	1
16	Measurement of Phosphocreatine in Cutaneous Tissue by High Pressure Liquid Chromatography The American Journal of the Medical Sciences ·Alexander Zemtsov, Gregory S. Cameron, Gáabor Töath, Georgia Moschovi	1993	15
17	Tumour promoter-induced release and metabolism of arachidonic acid: Comparison between mouse and human epidermal cells Toxicology in Vitro ·Gregory S. Cameron, Mark F. Naylor, Rebecca Morris, Lina María Vargas Álvarez, Kelly E. Patrick, NTT通信機器事業推進部, Susan M. Fischer	1992	4
18	Effects of Multiple Applications of Tumor Promoters and Ultraviolet Radiation on Epidermal Proliferation and Antioxidant Status Journal of Investigative Dermatology ·Gregory S. Cameron, Barbara C. Pence	1992	11
19	Arachidonic Acid Metabolism Varies with the State of Differentiation in Density Gradient-Separated Mouse Epidermal Cells Journal of Investigative Dermatology ·Gregory S. Cameron, Rudy Prayogo, Zhen Wang, Kelly E. Patrick, Susan M. Fischer	1990	22
20	Reactive oxygen in the tumor promotion stage of skin carcinogenesis Lipids ·Susan M. Fischer, Gregory S. Cameron, Rudy Prayogo, Zhen Wang, Kelly E. Patrick	1988	41

About Gregory S. Cameron

Gregory S. Cameron is a scholar working on Dermatology, Immunology, Biochemistry, Pathology and Forensic Medicine and Pharmacology, having authored 40 papers that have together received 4.1k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (12 papers), Dermatology and Skin Diseases (9 papers), Autoimmune Bullous Skin Diseases (6 papers), Polyamine Metabolism and Applications (6 papers), Asthma and respiratory diseases (6 papers), Inflammatory mediators and NSAID effects (5 papers), Skin Protection and Aging (3 papers) and Peroxisome Proliferator-Activated Receptors (3 papers). The work is most often cited by research in Dermatology (1.8k citations), Immunology (2.8k citations), Endocrine and Autonomic Systems (278 citations), Rheumatology (533 citations) and Hematology (366 citations). Gregory S. Cameron has collaborated with scholars based in United States, Japan and United Kingdom. Frequent co-authors include Craig L. Leonardi, Subhashis Banerjee, Daniel Braun, Emily Edson‐Heredia, Claus Zachariae, Daniel Braun, J. Erickson, Linda Li, Robert Matheson and Olawale Osuntokun. Their work appears in journals such as Journal of the American Academy of Dermatology, Journal of Investigative Dermatology, New England Journal of Medicine, The Journal of Dermatology and British Journal of Dermatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact